Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its
Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally LONDON and SALT
12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX)
Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE:
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an
